

SAFETY DATA SHEET



GlaxoSmithKline

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Material **GOODYS EXTRA STRENGTH HEADACHE POWDER**

Synonyms PROJECT NASCAR * MFC# 10790-01-0002 * ASPIRIN, PARACETAMOL AND CAFFEINE, FORMULATED PRODUCT

Company Name GlaxoSmithKline, Corporate Environment, Health & Safety
980 Great West Road
Brentford, Middlesex TW8 9GS UK

UK General Information: +44-20-8047-5000
Transport Emergency (EU) +44-1865-407333
Medical Emergency +1-612-221-3999, Ext 221
Information and Advice: US number, available 24 hours
Multi-language response

GlaxoSmithKline, Corporate Environment, Health & Safety
2200 Renaissance Blvd, Suite 105
King of Prussia, PA 19406 US

US General Information: +1-888-825-5249
Transport Emergency (non EU) +1-703-527-3887
US number, available 24 hours
Multi-language response

2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients	CAS RN	Percentage
ASPIRIN	50-78-2	50
PARACETAMOL	103-90-2	25
CAFFEINE	58-08-2	3.1
NON-HAZARDOUS INGREDIENTS	Unassigned	21.9

3. HAZARDS IDENTIFICATION

Fire and Explosion Assume that this product is capable of sustaining combustion.

Health Eye irritant.
Exposure might occur via eyes; skin; inhalation;
Health effects information is based on hazards of components.

Environment Toxic to aquatic organisms.

4. FIRST-AID MEASURES

Ingestion	Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.
Inhalation	Using appropriate personal protective equipment, move exposed subject to fresh air. If breathing is difficult or ceases, ensure and maintain ventilation. Give oxygen as appropriate. The exposed subject should be kept warm and at rest. Obtain medical attention in cases of known or possible over exposure, or with symptoms including chest pain, difficulty breathing, loss of consciousness or other adverse effects, which may be delayed.
Skin Contact	Using appropriate personal protective equipment, remove contaminated clothing and flush exposed area with large amounts of water. Obtain medical attention if skin reaction occurs, which may be immediate or delayed.
Eye Contact	Wash immediately with clean and gently flowing water. Continue for at least 15 minutes. Obtain medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment	Medical treatment in cases of overexposure should be treated as an overdose of aspirin ; acetaminophen/paracetamol. Treat according to locally accepted protocols. For additional guidance, refer to the local poison control information centre.
Medical Conditions Caused or Aggravated by Exposure	None for occupational exposure.
Antidotes	No specific antidotes are recommended.

5. FIRE-FIGHTING MEASURES

Fire and Explosion Hazards	The combustibility of the product is not known, however the packaging is combustible.
Extinguishing Media	Water or foam extinguishers are recommended. Carbon dioxide or dry powder extinguishers may be ineffective.
Special Firefighting Procedures	For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapours might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters. If possible, contain and collect firefighting water for later disposal.
Hazardous Combustion Products	Toxic, corrosive or flammable thermal decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions	Wear protective clothing and equipment consistent with the degree of hazard.
Environmental Precautions	For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.
Clean-up Methods	Collect and place it in a suitable, properly labelled container for recovery or disposal.
Decontamination Procedures	No specific decontamination or detoxification procedures have been identified for this product.

7. HANDLING AND STORAGE

HANDLING

General Requirements No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.

STORAGE

No storage requirements necessary for occupational hazards. Follow product information storage instructions to maintain efficacy.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

INGREDIENT	PARACETAMOL
GSK Occupational Hazard Category	1
GSK Occupational Exposure Limit	4000 MCG/M3 (8 HR TWA)

INGREDIENT	CAFFEINE
GSK Occupational Hazard Category	2
GSK Occupational Exposure Limit	200 mcg/m3 (8 HR TWA)

PERSONAL PROTECTIVE EQUIPMENT

Eye Protection Wear approved safety glasses with side shields if eye contact is possible.

Other Equipment or Procedures None required for normal handling. Wash hands and arms thoroughly after handling.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance

Colour	White.
Physical Form	Powder.

10. STABILITY AND REACTIVITY

Stability This product is expected to be stable.

Conditions to Avoid None for normal handling of this product.

11. TOXICOLOGICAL INFORMATION

Oral Toxicity Adverse effects might occur following ingestion.

Inhalation Toxicity No studies have been conducted. Overexposure may result in irritation of the respiratory tract.

Skin Effects Irritation might occur following direct contact.

Eye Effects Severe irritation might occur following direct contact with eyes.

Sensitisation Sensitisation (allergic skin reaction) is not expected.

Genetic Toxicity Not expected to be genotoxic under occupational exposure conditions.

Carcinogenicity No components are listed as carcinogens by GSK, IARC, NTP or US OSHA. Not expected to produce cancer in humans under occupational exposure conditions.

Reproductive Effects No adverse effects have been reported following extensive use or exposure in humans.

Other Adverse Effects Overexposure in the workplace might have the following effects: impaired blood coagulation; symptoms of hypersensitivity (such as skin rash, hives, itching, and/or difficulty breathing); toxicity to the liver resulting in abnormal blood chemistry.

12. ECOLOGICAL INFORMATION

Summary This product contains an active ingredient that has been tested and which may be harmful if released directly to the environment. Appropriate precautions should be taken to limit release of this material to the environment. Local regulations and procedures should be consulted prior to environmental release.

ECOTOXICITY

Aquatic

Daphnid This mixture contains an active pharmaceutical ingredient that is toxic to daphnids.

13. DISPOSAL CONSIDERATIONS

Disposal Recommendations Collect for recycling or recovery if possible. The disposal method for rejected products/returned goods must ensure that they cannot be re-sold or re-used.

Regulatory Requirements Observe all local and national regulations when disposing of this product.

14. TRANSPORT INFORMATION

The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorised persons trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous goods for transport.

UN Classification and Labelling

Transport Information Transportation and shipping of this product is not restricted. It has no known, significant hazards requiring special packaging or labelling for air, maritime, US or European ground transport purposes.

15. REGULATORY INFORMATION

The information included below is an overview of the major regulatory requirements. It should not be considered to be an exhaustive summary. Local regulations should be consulted for additional requirements.

EU Classification and Labelling

None.

US OSHA Standard (29 CFR Part 1910.1200)

Classification Exempt when packaged for sale to consumers in a retail establishment.

Other US Regulations

TSCA Status Exempt

California Proposition 65 Contains aspirin, a material known to the state of California to cause the following: Developmental toxicity ; Female reproductive toxicity .

16. OTHER INFORMATION

References GSK Hazard Determination

Date Approved/Revised 16-Aug-2003

SDS Version Number 5

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.